Member Info for HereforHemo

Dear oh dear, 121 now says HEMO heading for chapter 11 lol. Nearly £10m in the bank, plenty of runway through phase 1/2a of CAR-T clinical trials and as the sensible have stated CAR-T will be sold for £150m plus way before additional funds are needed so a major can take it through phase 3 and production, allowing HEMO to focus on their CDX antibody and their CBR platform. Hope you get out of your suspended share 121, probably in time to get into HEMO at around 15-20p. As for Matt I’d listen to him, good shout on Prem so he certainly doesn’t need any advice from you, an abject failure of an investor.

Matt thought I’d repost this excellent tweet. Rather than rely on advice, look at the facts. Based upon the last two fundraisers, I’d history repeats itself you should be looking at a minimum of 3.3p and a maximum of 13.6p over the next two months. With CAR-T going to the clinic and two potential CBR updates personally I’d expect something towards the upper end. Good luck.

https://twitter.com/Barneyboysrb/status/1641761984499548160?s=20

Matt Hemogenyx have applied. Decision should have been made on the 21st. Governor issued press release on the 11th April last year so we should know whether Hemogenyx have been successful with their CBR application shortly. It would mean up to $4m in matched funds and a fast track into clinical trials if successful.

https://esd.ny.gov/biodefensefund

Surprised they didn’t mention China much in that article as there’s also rapid growth of CAR-T therapy there. Think with our collaboration with WuXi it would be highly significant if we could get patent protection in China for CAR-T to go with CDX which is already approved, thus protecting our IP in the two biggest global markets.

HT you are of course right. Very surprising that positive messages were relayed from the company, Vlad himself tweeted he was ‘****ing excited’, then they announce a placing, then go into radio silence. You could almost think it was planned. I certainly won’t be talking to them again, absolutely no point.

Mr I for once I sincerely hope we don’t get an update next week and you can sell your remaining 2/3m shares and just **** off.

I see our distressed seller has continued to offload. No need for me to call him out again but at hopefully he’ll be totally out soon. At least when he’s selling it stops him whining every day!

Pawn re your post 8.58 that’s my understanding.

Before the trolls attack, just to clarify I have no dates it’s just my opinion. HEMO have entered stealth mode, there will be no leaks, no news to trade upon, news will arrive when it arrives and when it does it’ll be major!

Having been in communication with HEMO I see no reason why the IND for HEMO CAR-T is not submitted by next week at the latest. HEMO on the brink of becoming a clinical company, and the subsequent rerate we’ve all been looking forward to. GLA

Whilst I agree it would be pretty miraculous for all product candidates to succeed I believe that CAR-T looks extremely promising and Vlad himself said the reason PQ runs and analytical tests would take so long is they wanted to be certain it worked. Assuming it does it becomes a major validation of the scientific work Hemogenyx are doing, therefore the probability of their bi specific antibody working also increases. And if these two work what’s to say their CBR platform wouldn’t be all they say it is? I think we’ll soon know as if they get the bio defence grant that’s a major step forward in itself. The risk versus the reward in this share is simply staggering imo.

The important thing in that response is the company are progressing initiatives, in the plural. We know HEMO CAR-T IND will be submitted shortly and clinical trials will follow and that product alone will be worth hundreds of millions (at over $400,000 per patient) but they are also making tremendous progress on their CBR platform, potentially to cure any virus and become a new way of treating cancer. Don’t forget it as a seminal patent application, for those who don’t know the word, something is called seminal when it’s so original so groundbreaking and so awesome it will influence everything that comes after it. It’s little wonder Hemogenyx refer to it as ‘the Microsoft of the pharmaceutical world’. Could be life changing for all investors as well. We’ll soon know with in vivo results due as well as a potential bio defence grant. Very exciting times!

121 I’m sure you’re right, they’ll be a delay of at least 8 years on CAR-T, CDX is consigned to the bin and CBR is nothing but an illusion, and I’m sure you’re right about funding as well, regardless of Hemogenyx having nearly £10m in the bank I’m sure they’ll be raising funds every two months for the next five years. Ohh. and you really should take your doctors advice and take your medication and let’s hope when you’re captured they put a stronger lock on that asylum door. Maybe you’ll be out of that suspended share and be able to invest in HEMO by the time you next see freedom lol.

There’s nothing in there that will affect HEMO CAR-T timelines. People will always throw up obstacles that don’t exist. IND is very close and clinical trials will follow shortly after. Anything on CBR that’s released in parallel will make the end of year report very interesting indeed. Hemogenyx on the brink of greatness. Been a long wait but it will be so worthwhile for all invested and not just wealth, a sense of pride as well. All in my opinion.

Hemogenyx have had two months since the last PQ run to prepare the IND application. I see no reason why they wouldn’t just include the latest analytical results into the document and submit it next week.

Waiting no surprise you’re a Guinness man like me. 121 back filtered, off to get very drunk with an eye on some brilliant HEMO news coming very soon. Enjoy your weekend for all those invested.

121 you are clearly mentally challenged so I’ll try and simplify things for you. NO Hemogenyx did not buy the IP back from Eli. It is THEIR product and HEMO own the IP. Payment was made to Eli for purely the work Eli did to take the candidate forward. Surely even you can understand that???

121 you really are ****ing clueless! Hemogenyx ALWAYS owned the IP for CDX and it’s patent protected. They paid Eli 250k for their multi million pounds work they jointly did on developing it, which was an absolute steal. If you’re going to post please try and research some actual facts lol

It sounds to me our happy friend 121 is stuck in another share and desperately wants to get into HEMO as low as possible lol. Tick tock you muppet, hope you’re shafted next week hahahaha

God the desperation shows no bounds by posting a very old piece of news. Since that Hemogenyx have not only got patent protection for CDX but have joint patent applications with Eli pending, have agreed all licensing for CDX moving forward plus they’ve developed a master cell line in collaboration with Selexis. Keep up man! By the way, thanks for pointing out to investors that’s the THIRD viable product candidate for the clinic. Onwards.